NuVox Pharma Invested 2023

NuVox Pharma, LLC, is a clinical stage biotechnology company developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. The first drug candidate demonstrates great progress in improving the flow of oxygen from lungs to blood and from blood to tissue thereby amplifying the effectiveness of treatment. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF). Nuvox was co-founded by serial biotech entrepreneur, Evan Unger, MD, who in-licensed the core patents and obtained ownership of the regulatory documents for NuvOx’s key product. Dr. Unger is an inventor on over 120 issued U.S. patents. He is a board-certified radiologist and Professor Emeritus of Medical Imaging at the University of Arizona.